Anthropic Products
All Anthropic Release Notes (391)
- Jan 16, 2026
- Parsed from source:Jan 16, 2026
- Detected by Releasebot:Jan 17, 2026
- Modified by Releasebot:Jan 21, 2026
January 16, 2026
Cowork research preview expanded to Pro plans
Cowork is now available to Pro plan users on Claude Desktop (macOS only).
Claude Code access added to Team plan Standard seats
We’re now including Claude Code access with every Team plan standard seat. Refer to this article for more information: Purchasing and managing seats on Team plans .
Opus 4 and 4.1 deprecated from Claude and Claude Code
We’ve removed Claude Opus 4 and 4.1 from the Claude model selector and Claude Code. Refer to this article for further details and recommendations: Adapting to new model personas after deprecations .
Original source Report a problem - Jan 16, 2026
- Parsed from source:Jan 16, 2026
- Detected by Releasebot:Jan 17, 2026
- Modified by Releasebot:Jan 21, 2026
January 16, 2026
Cowork research preview expanded to Pro plans
Cowork is now available to Pro plan users on Claude Desktop (macOS only).
Claude Code access added to Team plan Standard seats
We’re now including Claude Code access with every Team plan standard seat. Refer to this article for more information: Purchasing and managing seats on Team plans.
Opus 4 and 4.1 deprecated from Claude and Claude Code
We’ve removed Claude Opus 4 and 4.1 from the Claude model selector and Claude Code. Refer to this article for further details and recommendations: Adapting to new model personas after deprecations.
Original source Report a problem - Jan 15, 2026
- Parsed from source:Jan 15, 2026
- Detected by Releasebot:Jan 15, 2026
Anthropic Economic Index report: economic primitives
New economic primitives reveal how Claude is used across tasks, education, work, and personal use, backed by the largest Claude.ai dataset to date. The report shows geographic and task-level insights ahead of Opus 4.5, signaling a data-led view of AI impact and productivity.
Introduction
This report introduces new metrics of AI usage to provide a rich portrait of interactions with Claude in November 2025, just prior to the release of Opus 4.5. These “primitives”—simple, foundational measures of how Claude is used, which we generate by asking Claude specific questions about anonymized Claude.ai and first-party (1P) API transcripts—cover five dimensions relevant to AI’s economic impact: user and AI skills, how complex tasks are, the degree of autonomy afforded to Claude, how successful Claude is, and whether Claude is used for personal, educational, or work purposes.
The results reveal striking geographic variation, real-world estimates of AI task horizons, and a basis for revised assessments of Claude's macroeconomic impact.
The data we release alongside this report are the most comprehensive to date, covering five new dimensions of AI use, consumer and firm use, and country and region breakdowns for Claude.ai.
In the first chapter, we revisit findings from our previous Economic Index report published in September 2025. We find:
- Claude usage remains concentrated among certain tasks, most of them related to coding
While we see over 3,000 unique work tasks in Claude.ai, the top 10 most common tasks account for 24% of our sampled conversations, a slight increase since our last report. Augmentation patterns (conversations where the user learns, iterates on a task, or gets feedback from Claude) edged to just over half of conversations on Claude.ai. In contrast, automated use remains dominant in 1P API traffic, reflecting its programmatic nature. - Global usage remains persistently uneven while US states converge
The US, India, Japan, the UK, and South Korea lead in overall Claude.ai use. Worldwide, uneven adoption remains well-explained by GDP per capita. Within the US, workforce composition plays a key role in shaping uneven adoption as states with more computer and mathematical professionals show systematically more Claude usage.
While substantial concentration remains, since our last report Claude usage has become noticeably more evenly distributed across US states. If sustained, usage per capita would be equalized across the country in 2-5 years.
In the second chapter
In the second chapter we discuss the motivation for and introduce our new economic primitives, including how they were selected and operationalized, and their limitations. We additionally present evidence that our primitives capture directionally accurate aspects of underlying usage patterns as compared to external benchmarks. In chapters three and four we use these primitives to further investigate implications for adoption and productivity. We find:
- Claude use diversifies with higher adoption and income
While the most common use of Claude is for work, coursework use is highest in countries with the lowest GDP per capita, while rich countries show the highest rates of personal use. This aligns with a simple adoption curve story: early adopters in less developed countries tend to be technical users with specific, high-value applications or use Claude for education, whereas mature markets see usage diversify toward casual and personal purposes. - Claude succeeds on most tasks, but less so on the most complex ones
We find that Claude generally succeeds at the tasks it is given, and that the education level of its responses tends to match the user's input. Claude struggles on more complex tasks: As the time it would take a human to do the task increases, Claude’s success rate falls, much like prominent evals measuring the longest tasks that AIs can reliably perform. - Job exposure to AI looks different when success rates are factored in
We also use the success rate primitive to better understand job exposure to AI, calculating the share of each occupation that Claude can perform by weighting task coverage by both success rates and the importance of each task within the job. For some occupations, like data entry keyers and database architects, Claude shows proficiency in large swaths of the job. - Claude is used for higher-skill tasks than those in the broader economy
The tasks we observe in Claude usage tend to require more education than those in the broader economy. If we assume that AI-assisted tasks diminish as a share of worker responsibilities, removing them would leave behind less-skilled work. But this simple task displacement would not affect white-collar workers uniformly—for some occupations it removes the most skill-intensive tasks, for others the least.
Without the tasks that we observe Claude performing, travel agents would experience deskilling as complex planning work gives way to routine ticket purchasing and payment collection. Property managers, by contrast, would experience upskilling as bookkeeping tasks give way to contract negotiations and stakeholder management.
These results provide a new window into how AI is currently impacting the economy. Knowing the success rate of tasks gives a more accurate picture of which tasks might be automated, how impacted certain jobs might be, and how labor productivity will change. Measuring differential performance by user education sheds light on inequality effects.
Indeed, the close relationship between education levels in inputs and outputs signals that countries with higher educational attainment may be better positioned to benefit from AI, independent of adoption rates alone.
This data release aims to enable researchers and the public to better understand the economic implications of AI and investigate the ways in which this transformative technology is already having an effect.
[The report continues with detailed chapters analyzing changes since the last report, introducing economic primitives, geographic variation in usage, task and productivity analysis, concluding remarks, authorship, acknowledgements, and citation information.]
Original source Report a problem - Jan 12, 2026
- Parsed from source:Jan 12, 2026
- Detected by Releasebot:Jan 12, 2026
- Modified by Releasebot:Jan 21, 2026
January 12, 2026
Claude updates roll out new Cowork preview on macOS desktop enabling local file access via VM and MCP integrations, plus health data analytics on Claude Mobile for Pro and Max plans with charts and US availability. Also introduces HIPAA-ready Enterprise plans for PHI processing.
Cowork research preview on Claude Desktop (macOS only) for Max plans
Cowork brings Claude Code's agentic capabilities to the Claude desktop app for knowledge work beyond coding. It runs locally on your computer in an isolated VM, enabling direct access to local files and MCP integrations.
Refer to this article to learn more: Getting Started with Cowork.
Health and fitness data on Claude Mobile
Claude can now read and analyze your health and fitness data on iOS and Android. Ask Claude about your activity patterns, workout trends, sleep quality, and more—Claude will provide insights and visualizations using native charts.
Health features are available on Pro and Max plans and currently limited to users in the US. On Android, Health Connect and Android 14 or later are required.
See the following articles for more information:
- Using Claude with iOS Apps
- Using Claude with Android Apps
HIPAA-ready Enterprise plans
We now offer a HIPAA-ready version of Claude that is available for organizations with Enterprise plans that choose to process protected health information (PHI) through Claude.
See HIPAA-Ready Enterprise Plans for more information.
Original source Report a problem - Jan 12, 2026
- Parsed from source:Jan 12, 2026
- Detected by Releasebot:Jan 13, 2026
Claude Developer Platform by Anthropic
January 12, 2026
console.anthropic.comnow redirects toplatform.claude.com. The Claude Console has moved to its new home as part of our Claude brand consolidation. Existing bookmarks and links will continue working via automatic redirect. For more details, see the September 16, 2025 announcement.
- Jan 12, 2026
- Parsed from source:Jan 12, 2026
- Detected by Releasebot:Jan 12, 2026
- Modified by Releasebot:Jan 21, 2026
January 12, 2026
Claude introduces Cowork desktop preview on macOS, bringing Code’s agentic capabilities to knowledge work with local VM access. Health insights arrive on Claude Mobile for US users on Pro/Max, with Android requirements; HIPAA-ready Enterprise plans expand PHI handling options.
Cowork research preview on Claude Desktop (macOS only) for Max plans
Cowork brings Claude Code's agentic capabilities to the Claude desktop app for knowledge work beyond coding. It runs locally on your computer in an isolated VM, enabling direct access to local files and MCP integrations.
Refer to this article to learn more: Getting Started with Cowork.
Health and fitness data on Claude Mobile
Claude can now read and analyze your health and fitness data on iOS and Android. Ask Claude about your activity patterns, workout trends, sleep quality, and more—Claude will provide insights and visualizations using native charts.
Health features are available on Pro and Max plans and currently limited to users in the US. On Android, Health Connect and Android 14 or later are required.
See the following articles for more information:
- Using Claude with iOS Apps
- Using Claude with Android Apps
HIPAA-ready Enterprise plans
We now offer a HIPAA-ready version of Claude that is available for organizations with Enterprise plans that choose to process protected health information (PHI) through Claude.
See HIPAA-Ready Enterprise Plans for more information.
Original source Report a problem - Jan 12, 2026
- Parsed from source:Jan 12, 2026
- Detected by Releasebot:Jan 13, 2026
January 12, 2026
console.anthropic.com now redirects to platform.claude.com. The Claude Console has moved to its new home as part of our Claude brand consolidation. Existing bookmarks and links will continue working via automatic redirect. For more details, see the September 16, 2025 announcement.
Original source Report a problem - Jan 11, 2026
- Parsed from source:Jan 11, 2026
- Detected by Releasebot:Jan 12, 2026
Advancing Claude in healthcare and the life sciences
Claude expands into Healthcare and Life Sciences with HIPAA-ready tools, new connectors (CMS, ICD-10, NPI, PubMed) and agent skills to speed prior authorization, coding, and trial management. Health data integrations and regulatory workflow enhancements broaden real‑world impact.
In October, we announced Claude for Life Sciences, our latest step in making Claude a productive research partner for scientists and clinicians, and in helping Claude to support those in industry bringing new scientific advancements to the public.
Now, we’re expanding that feature set in two ways. First, we’re introducing Claude for Healthcare, a complementary set of tools and resources that allow healthcare providers, payers, and consumers to use Claude for medical purposes through HIPAA-ready products. Second, we’re adding new capabilities for life sciences: connecting Claude to more scientific platforms, and helping it provide greater support in areas ranging from clinical trial management to regulatory operations.
These features build on top of major recent improvements we’ve made to Claude’s general intelligence. These improvements are best captured by evaluations of Claude’s agentic performance on detailed simulations of medical and scientific tasks, since this correlates most closely to real-world usefulness. Here, Claude Opus 4.5, our latest model, represents a major forward step:
In addition, Opus 4.5 with extended thinking improves on earlier Claude models in producing correct answers on our suite of honesty evaluations, reflecting the progress we’ve made on factual hallucinations.
With these model improvements and our new tools, Claude is now dramatically more useful for real-world healthcare and life sciences tasks. Ultimately, it’s those real-world outcomes that have motivated our work: these tools can be used to speed up prior authorization requests so that patients can get life saving care more quickly, can help with patient care coordination to reduce the pressures on clinicians' time, and help with regulatory submissions so that more life saving drugs can come to market faster. We discuss the practical ways that Claude can be used across these industries in more detail below.
Introducing Claude for Healthcare
What’s new
Connectors are tools that allow users to give Claude access to other platforms directly. For payers and providers, we’ve added several connectors that make healthcare information easier to find, access, and understand. These allow Claude to pull information from industry-standard systems and databases, meaning that clinicians and administrators can save significant time finding the data and generating the reports they need.
Claude can now connect to:
- The Centers for Medicare & Medicaid Services (CMS) Coverage Database, including both Local and National Coverage Determinations. This enables Claude to verify locally-accurate coverage requirements, support prior authorization checks, and help build stronger claims appeals. This connector is designed to help revenue cycle, compliance, and patient-facing teams work more efficiently with Medicare policy.
- The International Classification of Diseases, 10th Revision (ICD-10). Claude can look up both diagnosis and procedure codes to support medical coding, billing accuracy, and claims management. This data is provided by the CMS and the Centers for Disease Control and Prevention (CDC).
- The National Provider Identifier Registry, which allows Claude to help with provider verification, credentialing, networking directory management, and claims validation.
Since HIPAA-compliant organizations can now use Claude for Enterprise, they can also access existing healthcare-related connectors, including PubMed, which provides access to more than 35 million pieces of biomedical literature and allows Claude to quickly surface the latest research, and produce up-to-date literature reviews.
Finally, we’ve added two new Agent Skills: FHIR development and a sample prior authorization review skill. FHIR is the modern standard for exchanging data between healthcare systems, and this skill helps to improve interoperability by enabling developers to connect them faster and with fewer errors.
The prior authorization skill provides a template that can be customized to organizations’ policies and work patterns, helping with cross-referencing between coverage requirements, clinical guidelines, patient records, and appeal documents.
Using Claude for healthcare tasks
With these new tools, Claude can provide meaningful support for healthcare startups building new products, and for large enterprises looking to integrate AI more deeply into their operations. For example, Claude can:
- Speed up reviews of prior authorization requests. These requests can take hours to review, slowing patients’ access to care they need and frustrating payers and providers alike. Reviews require working across various fragmented sources of information, including coverage requirements, clinical guidelines, patient records, and appeal documents. Now, Claude can pull coverage requirements from CMS or custom policies, check clinical criteria against patient records in a HIPAA-ready manner, and then propose a determination with supporting materials for the payer’s review.
- Support claims appeals. Denied claims cost time and money for all parties. By pulling together the necessary information from patient records, coverage policies, clinical guidelines and prior documentation, Claude helps providers build stronger appeals, and helps payers to process them more quickly.
- Coordinate care and triage patient messages. Claude can support care teams in navigating a large volume of patient portal messages, referrals, and handoffs. It can sort through these to identify what needs immediate attention, and to ensure that nothing gets inadvertently forgotten.
- Support healthcare startups developing new ideas. On the Claude Developer Platform, startups can build new products that use Claude to reduce the time burden of healthcare administration—such as ambient scribing for clinical documentation, or tools to support chart reviews and clinical decisions.
Connecting personal health data
We’re also introducing integrations designed to make it easier for individuals to understand their health information and prepare for important medical conversations with clinicians.
In the US, Claude Pro and Max plan subscribers can choose to give Claude secure access to their lab results and health records. New HealthEx and Function connectors are available in beta today, while Apple Health and Android Health Connect integrations are rolling out in beta this week via the Claude iOS and Android apps.
When connected, Claude can summarize users’ medical history, explain test results in plain language, detect patterns across fitness and health metrics, and prepare questions for appointments. The aim is to make patients' conversations with doctors more productive, and to help users stay well-informed about their health.
These integrations are private by design. Users can choose exactly the information they share with Claude, must explicitly opt-in to enable access, and can disconnect or edit Claude’s permissions at any time. We do not use users’ health data to train models.
Claude is designed to include contextual disclaimers, acknowledge its uncertainty, and direct users to healthcare professionals for personalized guidance.
Expanding Claude for Life Sciences
What’s new
In our initial release, we focused on making Claude more powerful for preclinical research and development (including bioinformatics, and generating hypotheses and protocols). Now, we’re expanding our focus to the clinical trial operations and regulatory stages of the development chain. We’re adding connectors to:
- Medidata, a leading provider of clinical trial solutions to the life sciences industry. Through Medidata, you can give Claude access to your organization’s trial data, enrollment information, and information about site performance.
- ClinicalTrials.gov, the US clinical trials registry. This provides Claude with information on drug and device development pipelines, as well as patient recruitment planning, site selection, and protocol design.
- ToolUniverse, which allows scientists to use a library of over 600 vetted scientific tools to rapidly test hypotheses, compare approaches, and refine their analyses.
- bioRxiv & medRxiv, the life sciences preprint servers. When connected to bioRxiv & medRxiv, Claude can access the latest research before it’s formally published.
- Open Targets, which supports the systematic identification and prioritization of potential therapeutic drug targets.
- ChEMBL, the bioactive compound and drug database, which will help Claude support early discovery work.
- Owkin, whose Pathology Explorer agent analyzes tissue images to detect cells and map tumors, designed to accelerate drug discovery and development.
These join our existing Life Sciences connectors to Benchling, 10x Genomics, PubMed, BioRender, Synapse.org, and Wiley Scholar Gateway. Our Benchling connector is now also available via Claude.ai on the web (in addition to the Claude desktop app), with secure access via SSO.
Finally, we’re adding new Agent Skills for scientific problem selection, converting instrument data to Allotrope, and supporting bioinformatics work with skills bundles for scVI-tools and Nextflow deployment. We’re also adding a sample skill for clinical trial protocol draft generation. These drafts include endpoint recommendations and account for regulatory pathways, the competitive landscape, and relevant FDA guidelines.
See the clinical trial skill in action, below:
Using Claude in life sciences
With this new package of tools, Claude can support:
- Drafting clinical trial protocols. Claude can create a draft of a clinical trial protocol that takes FDA and NIH requirements into account and uses your organization’s preferred templates, policies, and datasets.
- Clinical trial operations. Using Medidata trial data, Claude can track important indicators—like enrollment and site performance—that allow it to surface issues before they begin to affect a trial’s timeline.
- Preparing regulatory submissions. Claude can identify gaps in existing regulatory documents, draft responses to agencies’ queries, and navigate FDA guidelines.
Our customers and partners
We’re working with a number of organizations in healthcare and the life sciences. A selection of our partners describe their experiences using Claude below:
- Banner Health: We were drawn to Anthropic's focus on AI safety and Claude's Constitutional AI approach to creating more helpful, harmless, and honest AI systems.
- Novo Nordisk: We've consistently been one of the first movers when it comes to document and content automation in pharma development. Our work with Anthropic and Claude has set a new standard — we're not just automating tasks, we're transforming how medicines get from discovery to the patients who need them. — Louise Lind Skov, Director Content Digitalisation, Novo Nordisk
- Qualified Health: Safety is non-negotiable in healthcare. Anthropic has been a clear leader in building models with strong safety foundations. — Justin Norden, MD and co-founder, Qualified Health
- Genmab: By reducing manual burden, our partnership with Anthropic will empower our teams to focus more time on high-value scientific and strategic work, accelerating our path to patient impact. — Hisham Hamadeh, Senior Vice President, Global Head of Data, Digital & AI, Genmab
- Sanofi: Claude is integral to Sanofi's AI transformation and is used by most Sanofians daily. We're seeing efficiency gains across the value-chain. This collaboration with Anthropic augments human expertise to deliver life-changing medicines faster and more efficiently to patients worldwide. — Emmanuel Frenehard, Chief Digital Officer, Sanofi
- Elation Health: We chose Claude, powered by Anthropic, for the strength of its model and its reputation for responsible AI. That balance of performance plus trust was a decisive factor. — Kyna Fong, CEO & Co-Founder, Elation Health
- Edison Scientific: Opus 4.5 is an incredible model and a great choice for computational biology. The model is excellent at coding, reasoning about biology, and understanding scientific figures. — Andrew White, CTO, Edison Scientific
- Viz.ai: Anthropic's models are unmatched in their reasoning capabilities and safety design. — Chris Mansi, MD, CEO & Co-founder, Viz.ai
- Flatiron Health: Claude has fundamentally changed what's possible in evidence generation. For the first time, our researchers can truly converse with our datasets. — Allison Candido, Vice President & Head of Engineering, Flatiron Health
- Veeva AI: Veeva AI is industry-specific agentic AI that leverages Veeva's deep applications, data, domain expertise, and Anthropic’s Claude. This unique combination allows us to bring the transformative promise of AI to life sciences at scale. — Andy Han, Senior Vice President, Veeva AI
- Heidi Health: Claude's Agent SDK has unlocked a step-change in how we operate—converting rigid research processes into adaptive, compliant agents. — Dr. Thomas Kelly, Co-Founder and CEO, Heidi Health
- Schrödinger: Claude Code has become a powerful accelerator for us at Schrödinger. For the projects where it fits best, Claude Code allows us to turn ideas into working code in minutes instead of hours, enabling us to move up to 10x faster in some cases. As we continue to work with Claude, we are excited to see how we can further transform the way we build and customize our software. — Pat Lorton, EVP, Chief Technology Officer, and Chief Operating Officer, Schrödinger
- Premier: Claude handles the complex healthcare workflows our teams deal with daily—accurately and securely. Our engineers are shipping faster, our consultants are delivering insights with unprecedented speed. When you're serving 4,400+ healthcare organizations, that combination of capability and velocity is critical. — David Zito, President Performance Services, Premier
- Commure: For Commure’s Ambient AI, precision is the prerequisite for trust. Scaling to tens of millions of appointments requires exceptional performance and contextual understanding. With Claude’s suite of LLMs, we deliver the quality to automate clinical documentation at scale, saving clinicians millions of hours annually and returning their focus to patient care. — Dhruv Parthasarathy, Chief Technology Officer, Commure
- Carta Healthcare: Carta Healthcare's implementation of Anthropic models via Amazon Bedrock has allowed for rapid and secure deployment of the newest models. Unlocking our hybrid intelligence AI system that is turning into a complete re-invention of understanding a patient’s medical record for clinical data abstraction. — Andrew Crowder, VP of Engineering, Carta Healthcare
- Brellium: Claude lets us punch way above our weight in healthcare AI. It powers our clinical extraction engine, cuts implementation timelines, and gives our GTM team dev-level capabilities. The faster we build, the faster clinics get out of manual chart review and back to patients. — Zach Rosen, CEO & Co-Founder, Brellium
Claude is the only frontier model available on all three leading cloud services: AWS, Google Cloud, and Microsoft.
We’re also partnering with companies who specialize in helping organizations adopt AI for specialist work, including Accenture, Blank Metal, Caylent, Deloitte, Deepsense.ai, Firemind, KPMG, Provectus, PwC, OWT, Quantium, Slalom, Tribe AI, and Turing.
Getting started
To learn more about Claude for Healthcare, see here, or see our tutorial guides here. For more detail on the expanded Claude for Life Sciences capabilities, see here, and our tutorial guides here.
Our new connectors and Agent Skills are generally available to all Claude subscribers, including Claude Pro, Max, Teams, and Enterprise.
You can also contact our sales team to discuss bringing Claude to your organization.
Original source Report a problem - Jan 5, 2026
- Parsed from source:Jan 5, 2026
- Detected by Releasebot:Jan 6, 2026
Claude Developer Platform by Anthropic
January 5, 2026
- We've retired the Claude Opus 3 model (
claude-3-opus-20240229). All requests to this model will now return an error. We recommend upgrading to Claude Opus 4.5, which offers significantly improved intelligence at a third of the cost. Researchers can request ongoing access to Claude Opus 3 on the API through the External Researcher Access Program.
- Jan 5, 2026
- Parsed from source:Jan 5, 2026
- Detected by Releasebot:Jan 6, 2026
January 5, 2026
Model retirement notice
We've retired the Claude Opus 3 model (claude-3-opus-20240229). All requests to this model will now return an error. We recommend upgrading to Claude Opus 4.5, which offers significantly improved intelligence at a third of the cost. Researchers can request ongoing access to Claude Opus 3 on the API through the External Researcher Access Program.
Original source Report a problem